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Children With Autosomal Recessive
Polycystic Kidney Disease: A Comparative
Cohort Study of the International Pediatric
Peritoneal Dialysis Network RegistryTo the Editor:
ARPKD is a rare disorder but an important cause of
early-onset pediatric kidney failure.1-3 PD has been rec-
ommended as the method of choice for initiating dialysis
in infants and small children,4-6 but there are concerns
regarding the feasibility of maintenance PD in ARPKD
patients with their massively enlarged kidneys.2,7 Some
centers perform uni- or bilateral nephrectomies of native
ARPKD kidneys.8
To systematically evaluate maintenance PD characteris-
tics, residual kidney function, and patient and PD tech-
nique survival in pediatric ARPKD patients, we compared
data from the International Pediatric Peritoneal Dialysis
Network (IPPN) registry from children with ARPKD
(n = 79), CNS (n = 79), and CAKUT (n = 158; Tables 1
and S1). Groups were matched for age and time on dial-
ysis (Fig S1). PD modalities included CAPD and APD
(w80% of patients). Patients with highly individualized
regimens were excluded from the analysis of PD pre-
scription. Differences in PD prescription over observation
time were examined by linear mixed regression models
(Item S1; Table S2).
Overall peritoneal fill volumes of all PD modalities
combined were w15% lower in ARPKD patients
(704 ± 24 [SEM] vs 841 ± 24 and 822 ± 20 mL/m2/d for
CNS and CAKUT, respectively). This tendency was
confirmed in models accounting for PD modalities (Fig
1A; Table S3) or oligoanuria (Fig S2; Table S4). Among
CAPD patients, those with ARPKD received significantly
more cycles (Fig 1A). Among APD patients, number of
cycles and time spent on cycler were similar in all groups.
Due to lower fill volumes, ARPKD patients on APD ach-
ieved lower PD fluid turnover than CNS and CAKUT pa-
tients (Fig 1A). Lower PD fluid glucose concentrations
were prescribed in ARPKD patients on APD, resulting in
significantly lower peritoneal glucose exposure. Despite
this, ARPKD patients on APD achieved similar ultrafiltra-
tion volumes and thus had a higher ultrafiltration per
glucose exposure ratio (Fig 1A). It is tempting to speculate
that portal hypertension may add nonosmotic ultrafiltra-
tion in ARPKD patients.
At the baseline visit, 35 ARPKD, 39 CNS, and 23 CAKUT
patients were already anuric (Table 1). Urine output at
baseline was highest in CAKUT patients and lowest in CNSAJKD Vol 75 | Iss 3 | March 2020
Table 1. Patient and PD Characteristics at Enrollment, Incidence of PD Complications
ARPKD CNS CAKUT
P for ARPKD vs
CNS CAKUT
Characteristics
No. of patients 79 79 158
Age at BL visit, y 2.42 [0.84-6.77] 2.40 [0.78-5.56] 2.42 [0.80-6.76] 0.8 0.9
Age at start of current PD, y 1.28 [0.08-4.45] 1.53 [0.49-4.44] 1.27 [0.08-4.31] 0.1 0.9
Age at start of first KRT,a y 0.58 [0.05-3.46] 1.50 [0.49-4.16] 1.08 [0.07-4.16] 0.02 0.3
PD duration at BL visit, mo 4.0 [0.9-16.2] 3.4 [1.0-12.5] 3.8 [1.1-14.8] 0.7 0.9
F/U time, mo 13.2 [5.6-25.3] 8.4 [3.3-17.8] 12.7 [4.7-24.1] 0.1 0.9
Male sex 37 (47%) 43 (54%) 124 (78.5%) 0.3 <0.001
Anthropometric data at BL visit
Height, SDS −2.69 ± 1.48 −2.38 ± 1.76 −2.86 ± 1.74 0.2 0.4
Body mass index, SDS 0.34 ± 1.64 −0.04 ± 1.55 −0.03 ± 1.41 0.1 0.08
Urine output at BL visitb
Urine output, mL/m2/d 145 [0-1,071] 37 [0-586] 848 [378-1,516] 0.07 <0.001
Pts with oligoanuria 35 (49%) 39 (56%) 23 (16.7%) 0.4 <0.001
PD modality at BL visit 0.3 0.9
CAPD 17 (22%) 15 (19%) 32 (20.3%)
APD (NIPD) 40 (51%) 32 (41%) 80 (50.6%)
APD (CCPD) 21 (27%) 29 (37%) 43 (27.2%)
Other 1 (1%) 3 (4%) 3 (1.9%)
PD fluids at BL visit 0.8 0.1
Acidic lactate 40 (51%) 38 (48%) 96 (60.8%)
pH-neutral fluid 39 (49%) 41 (52%) 62 (39.2%)
Complications During F/Uc n = 37 n = 38 n = 75
Exit-site and tunnel infections
Rate per patient-y of F/Ud 0.06 0.15 0.23
Pts with ≥1 infection 2 (5%) 5 (13%) 15 (20%) 0.2 0.04
Pts with >1 infection 1 (3%) 2 (5%) 5 (7%) 0.6 0.4
Peritonitis episodes
Rate per patient-y of F/Ud 0.48 0.66 0.56
Pts with ≥1 episode 12 (32%) 11 (29%) 25 (33%) 0.7 0.9
Pts with >1 episode 4 (11%) 8 (21%) 14 (19%) 0.2 0.3
Access revisions
Rate per patient-y of F/Ud 0.27 0.09 0.23
Pts with ≥1 revision 8 (22%) 3 (8%) 18 (24%) 0.09 0.8
Pts with >1 revision 4 (11%) 1 (3%) 3 (4%) 0.2 0.2
Note: Unless otherwise indicated, data are count (percent), median [interquartile range], or mean ± SD. P values are based on χ2, Mann-Whitney U, or t tests.
Abbreviations: APD, automated peritoneal dialysis; BL, baseline; CAPD, continuous ambulatory peritoneal dialysis; CAKUT, congenital anomalies of the kidneys and
urinary tract; CCPD, continuous cycling peritoneal dialysis (APD with daytime dwell[s]); CNS, congenital nephrotic syndrome; F/U, follow-up; KRT, kidney replacement
therapy; NIPD, nocturnal intermittent peritoneal dialysis (APD without daytime dwell); PD, peritoneal dialysis; SD, standard deviation; SDS, standard deviation score.
aAge at earliest initiation of KRT and includes KRT before current PD; ARPKD, n = 78; CAKUT, n = 154.
bAvailable urine data at BL: ARPKD, n = 72; CNS, n = 70; CAKUT, n = 138; oligoanuria defined as urine output < 100 mL/m2/d.
cOnly includes pts followed up from start of PD, pts with first visit >3 mo after PD starting date excluded.
dPatient-years of F/U defined as sum of F/U years per pt; total patient-years of F/U: ARPKD, 48; CNS, 46; CAKUT, 95.
Correspondencepatients, and the latter showed more frequent and earlier
onset of oligoanuria over the course of PD (Fig S3). Pa-
tients with and without oligoanuria differed in key PD
parameters, though mostly independent of the renal
diagnosis (Fig S2; Table S4).
In incident maintenance PD patients (Table S5), exit-site
and tunnel infections were reported less frequently in
ARPKD than CAKUT patients (0.06 vs 0.23 episodes/year),
whereas peritonitis frequency did not differ (Table 1). The
need for PD access revisions in ARPKD patients was higher
than in CNS patients but similar to CAKUT patients
(Table 1). There were no significant differences inAJKD Vol 75 | Iss 3 | March 2020hospitalizations (Table S6) or anthropometric or metabolic
parameters (Table S7).
Death on dialysis was observed in 13 ARPKD, 13 CNS, and
8 CAKUT patients (Table S8) with cumulative survival rates
after 4 years on PD of 78% in ARPKD, 73% in CNS, and 95%
in CAKUT (Fig S4). Patient age and the CAKUT diagnosis
were inversely correlated with mortality (Fig S4; Table S9).
While mortality was generally higher in patients who
commenced PD in the first year of life, survival in this age
group did not differ between ARPKD and CNS (Table S10).
PD technique survival rate was w80% after 4 years,




























































































































































































































Figure 1. (A) PD prescription in patients. (B) Kaplan-Meier PD technique survival curves. (A) Data shown as model parameter es-
timates (mean and 95% confidence interval) and are based on linear mixed regression models (LMMs) for the entire observation time
with an interaction term between diagnosis (ARPKD, CNS, CAKUT) and PD modality (CAPD, APD) (Total N: ARPKD, 72; CNS, 72;
CAKUT, 144; Tables S2, S3); P values for CAPD are based on LMM with ARPKD/CAPD as reference group; P values for APD are
based on LMM with ARPKD/APD as reference group. UF/GLU-ratio: ratio between ultrafiltration volume (L/m2/d) and glucose expo-
sure (g/kg/d). (B) PD technique failure defined as switch to hemodialysis, death, or termination due to PD complications (infectious or
noninfectious).
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Correspondence
CorrespondenceTable S11). Younger patients had higher risk for PD
technique failure (Table S11).
Our study has some limitations. Because IPPN focuses
on PD-related information, genotypes, hepatic involve-
ment, gastrostomy tube insertion, vesicostomies, or ne-
phrectomies were not systematically documented. Such
data are currently collected in disease-specific cohort
studies.9,10 Because the median age at baseline was 2.4
years, we may have missed early-onset disease-specific
aspects. Furthermore, reporting bias cannot be excluded
due to the voluntary nature of the registry. Potential
regional practice specificities cannot be sufficiently
addressed.
In summary, maintenance PD can be performed suc-
cessfully in children with ARPKD, with good patient sur-
vival and comparable technique outcomes as observed in
other early-onset kidney diseases. Minor adaptations of PD
prescription are usually required, probably to comply with
the large kidney size. Remarkably, higher ultrafiltration per
glucose ratios are achieved in children with ARPKD on
APD, possibly related to portal hypertension.
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